REFERENCES


6. Dandekar PK, Maglio D, Sutherland CA, et al. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy. 2003;23:988-991.


References


49. Ambroso PG, Grasela DM, Grasela TH, et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in...


Chapter 62

REFERENCES

References


76. Muehlstedt SG, Lyte M, Rodriguez JL. Increased IL-10 production and HLA-DR suppression in the lungs of injured patients precede the development of nosocomial pneumonia. Shock. 2002;17:443-450.


References


Chapter 63

REFERENCES

References


Chapter 64

REFERENCES


References


78. Haasper C, Kalmbach M, Dikos GD, et al. Prognostic value of procalcitonin (PCT) and/or interleukin-6 (IL-6) plasma levels after multiple trauma for the development of multi organ dysfunction syndrome (MODS) or sepsis. Technol Health Care. 2010;18(2):89-100.


REFERENCES


References


Chapter 66

REFERENCES

REFERENCES


Chapter 68

REFERENCES


References


References


450. Walsh TJ, et al. A randomized, double-blind, multicenter trial of caspofungin versus liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients. 43rd International Conference on Antimicrobial Agents and Chemotherapy; 2003; Chicago, IL.


References


REFERENCES


References


References


References


References


Chapter 70

REFERENCES


26. Davis SL, Vazquez JA, McKinnon PS. Epidemiology, risk factors, and outcomes of *Candida albicans* versus non-*albicans*


REFERENCES


Chapter 72

REFERENCES


44. Griffiths P. Cytomegalovirus infection of the central nervous system. *Herpes*. 2004;11(suppl 2):95A-104A.


References


REFERENCES


REFERENCES


REFERENCES


References


REFERENCES


Chapter 77

REFERENCES


Chapter 78

REFERENCES


Chapter 80

REFERENCES


References


Chapter 81

REFERENCES


